LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

36.52 2.33

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

35.66

Max

37.88

Põhinäitajad

By Trading Economics

Sissetulek

-20M

-85M

Kasumimarginaal

-867.293

Töötajad

316

EBITDA

-21M

-94M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+52.83% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

11. nov 2025

Turustatistika

By TradingEconomics

Turukapital

158M

2.8B

Eelmine avamishind

34.19

Eelmine sulgemishind

36.52

Uudiste sentiment

By Acuity

50%

50%

167 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. sept 2025, 23:01 UTC

Omandamised, ülevõtmised, äriostud

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17. sept 2025, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17. sept 2025, 21:59 UTC

Tulu

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17. sept 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17. sept 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17. sept 2025, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17. sept 2025, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17. sept 2025, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17. sept 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17. sept 2025, 22:18 UTC

Omandamised, ülevõtmised, äriostud

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17. sept 2025, 21:00 UTC

Tulu

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17. sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. sept 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. sept 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17. sept 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17. sept 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17. sept 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17. sept 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17. sept 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. sept 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17. sept 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17. sept 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17. sept 2025, 17:15 UTC

Omandamised, ülevõtmised, äriostud

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17. sept 2025, 17:06 UTC

Omandamised, ülevõtmised, äriostud

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17. sept 2025, 16:51 UTC

Tulu

Correct: Exor 1H Net Loss -EUR624M

17. sept 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. sept 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17. sept 2025, 16:25 UTC

Tulu

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17. sept 2025, 16:23 UTC

Tulu

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

52.83% tõus

12 kuu keskmine prognoos

Keskmine 54.5 USD  52.83%

Kõrge 65 USD

Madal 48 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

12

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

167 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat